{"nctId":"NCT01624233","briefTitle":"A Study in Japanese Participants With Moderate-to-Severe Psoriasis","startDateStruct":{"date":"2012-06"},"conditions":["Psoriasis"],"count":91,"armGroups":[{"label":"80 mg ixekizumab","type":"EXPERIMENTAL","interventionNames":["Drug: 80 mg ixekizumab"]}],"interventions":[{"name":"80 mg ixekizumab","otherNames":["LY2439821"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men must agree to use a reliable method of birth control during the study\n* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment\n* Candidates for phototherapy and/or systemic therapy\n* Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment\n* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis\n* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis\n\nExclusion Criteria:\n\n* History of drug-induced psoriasis\n* Concurrent or recent use of any biologic agent\n* Received systemic psoriasis therapy \\[such as psoralen and ultraviolet A (PUVA) light therapy\\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis\n* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study\n* Have participated in any study with interleukin-17(IL-17) antagonists, including ixekizumab\n* Serious disorder or illness other than psoriasis\n* Serious infection within the last 3 months\n* Breastfeeding or nursing (lactating) women\n* Clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving ≥75% Improvement in Psoriasis Area and Severity Index (PASI) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis. Measure: PASI)","description":"The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \\* area score \\* weighing factor \\[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving ≥75% Improvement in PASI","description":"The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region, the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \\* area score \\* weighing factor \\[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics (PK): Ctrough at Steady State (Ctrough ss) of Ixekizumab","description":"PK samples were from 1 or 2 sampling cohorts. Ctrough is the minimum observed concentration of ixekizumab at steady state. Steady-state ixekizumab trough concentrations were summarized for the induction dosing period at week 12, the time of the primary efficacy assessment. Steady-state ixekizumab trough concentrations were summarized for the maintenance dosing period at week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.63","spread":"43.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.48","spread":"65.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Anti-Ixekizumab Antibodies","description":"Treatment-emergent immunogenicity is defined as any occurrence of a 4-fold or 2-dilution increase in titer over the pretreatment baseline titer. In the case of a negative result at baseline, treatment-emergent immunogenicity is defined as an increase in titer to ≥1:10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Achieving PASI 90% and 100% Improvement","description":"The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \\* area score \\* weighing factor \\[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Static Physician Global Assessment (sPGA) (0 or 1) or sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Psoriasis Measure: sPGA)","description":"The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percent of Body Surface Area (BSA) Involvement","description":"BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.3","spread":"19.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-41.2","spread":"20.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.8","spread":"19.73"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Nail Psoriasis Severity Index (NAPSI)","description":"The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all fingernails equals the total NAPSI score with a range from range 0 to 80. Higher scores indicated more severe psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.7","spread":"14.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.5","spread":"19.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.4","spread":"23.67"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Psoriasis Scalp Severity Index (PSSI)","description":"The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.8","spread":"15.12"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.9","spread":"15.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.3","spread":"16.48"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Reported 16 Items (QIDS-SR16) Score [Quality of Life and Outcome Assessments. Measures: Patient Reported Outcomes (PRO)]","description":"QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst). The sum of the 16 items corresponding to 9 depression domains \\[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\\] to give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"3.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"3.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"3.57"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Itch Numeric Rating Scale (NRS) Score","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"2.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"2.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"2.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Dermatology Life Quality Index (DLQI) Score","description":"DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (\"not relevant\") responses were scored as \"0.\" Total scores range from 0 to 30, with higher score indicating greater quality of life is impairment. A 5-point increase in total score from baseline is considered clinically relevant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"5.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.2","spread":"6.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"6.24"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving American College of Rheumatology 20% (ACR20) Improvement [Efficacy of Ixekizumab in Participants With Psoriatic Arthritis (PsA) as Measured by ACR20]","description":"ACR20 response is defined as a ≥20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain visual analog scale (VAS), Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or C-reactive protein (CRP) or the erythrocyte sedimentation rate (ESR).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participants Assessment of Joint Pain Visual Analog Scale (VAS) (Efficacy of Ixekizumab in Participants With PsA Pain VAS)","description":"The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0 mm (no pain) to 100 mm (pain as severe as you can imagine).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-47.3","spread":"22.05"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.0","spread":"19.05"}]}]}]},{"type":"SECONDARY","title":"Percent of Participants Achieving PASI 75%, 90% and/or 100% Improvement","description":"The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated: 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling, with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI=sum of severity parameters for each region \\* area score \\* weighing factor \\[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With sPGA (0 or 1) and sPGA (0)","description":"The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear) or 1 (minimal).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Percent of BSA Involvement","description":"BSA is a physician rating of the percentage of involvement of Ps for each participant. BSA is assessed on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participants hand (includes the palm, fingers and thumb).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-24.7","spread":"17.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-40.2","spread":"21.18"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in NAPSI","description":"The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail Ps. This scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement in the fingernail unit. The fingernail is divided with imaginary horizontal and longitudinal lines into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants in matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The NAPSI score of a fingernail is the sum of scores in fingernail bed and fingernail matrix from each quadrant (maximum of 8). Each fingernail is evaluated, then the sum of all the fingernails equals the total NAPSI score with a range 0 to 80. Higher scores indicate more severe psoriasis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":"19.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.4","spread":"26.31"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in PSSI","description":"The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\\<10%) to 6 (90%-100%) with a total scores range from 0 to 72, with lower scores indicating less severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"16.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.2","spread":"15.17"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in QIDS-SR16 Score","description":"QIDS-SR16 is a participant-administered, 16-item instrument intended to assess the existence and severity of symptoms of depression. A participant is asked to consider each statement as it relates to the way they have felt for the past 7 days and rate each on a 4-point scale: 0 (best) to 3 (worst) scale. The sum of the 16 items corresponding to 9 depression domains \\[sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance (initial, middle and late insomnia or hypersomnia), decrease/increase in appetite/weight, and psychomotor agitation/retardation\\] give a single total scores range from 0 to 27, with higher scores indicating greater symptom severity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"4.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"3.87"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Itch NRS Score","description":"The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10, (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"2.62"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"2.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in DLQI Score","description":"DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much) and unanswered (\"not relevant\") responses were scored as \"0.\" Total scores range from 0 to 30, with higher scores indicating greater quality of life impairment. A 5-point increase in total score from baseline is considered clinically relevant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.9","spread":"5.70"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Participants Assessment of Joint Pain VAS","description":"The pain VAS is a participant-administered single-item scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by placing a single mark on the horizontal 100-mm scale from 0mm (no pain) to 100 mm (pain as severe as you can imagine).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.8","spread":"39.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.8","spread":"25.66"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving ACR20","description":"ACR20 response is defined as ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: participant's assessment of Joint Pain VAS, Patient's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, participant's assessment of physical function using the HAQ-DI, or CRP or the ESR.\n\nAnalysis population included participants with PsA who had 3 or more tender joints and 3 or more swollen joints at screening and baseline.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":91},"commonTop":["Viral upper respiratory tract infection","Eczema","Influenza","Arthralgia","Back pain"]}}}